Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S048000, C546S050000, C544S111000, C544S125000
Reexamination Certificate
active
06933302
ABSTRACT:
(20) esters of camptothecin analogs are provided. The compounds are (20) esters of an aminoalkanoic acid or an imidoalkanoic acid and homocamptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the homocamptothecin ring. The compounds are useful for treating cancer.
REFERENCES:
patent: 4399282 (1983-08-01), Miyasaka
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 5916896 (1999-06-01), Wall et al.
patent: 5965566 (1999-10-01), Greenwald et al.
patent: 6028078 (2000-02-01), Hausheer et al.
patent: 6040313 (2000-03-01), Wall et al.
patent: 6057303 (2000-05-01), Haridas et al.
patent: 6096336 (2000-08-01), Cao et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6114529 (2000-09-01), Kawaguchi et al.
patent: 6120793 (2000-09-01), Cao et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6153655 (2000-11-01), Martinez et al.
patent: 6207832 (2001-03-01), Curran et al.
patent: 6339091 (2002-01-01), Bigg et al.
patent: 6350756 (2002-02-01), Yang et al.
patent: 6403604 (2002-06-01), Yang et al.
patent: 0 861 842 (1998-09-01), None
patent: 2524804 (1996-08-01), None
patent: WO 95/10304 (1995-04-01), None
patent: WO 96/26950 (1996-09-01), None
patent: WO 97/19085 (1997-05-01), None
patent: WO 97/28165 (1997-08-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 98/14459 (1998-04-01), None
patent: WO 98/28304 (1998-07-01), None
patent: WO 98/35940 (1998-08-01), None
patent: WO 98/51703 (1998-11-01), None
patent: WO 99/17805 (1999-04-01), None
patent: WO 00/66127 (2000-11-01), None
patent: WO 00/67801 (2000-11-01), None
patent: WO 03/014069 (2003-02-01), None
English Abstract DN 112:158710 Nagao Yoshimitsu et al Aug. 1996.
Franciscus M et al , May 2002 Novel 20-carbononate Linked prodrugs of Camptothecin . . . pp. 2371-2376.
Olivier Lavergne et al Jul. 1998,Homocamptothecins . . . , 5410-5419.
Oliveir Lavergne et al et al Mar. 2000 , Topoisomerase I- mediated . . . pp. 2285-2289.
Laurence Lesueur -Ginot et al Jun. 1999, Homocamptothecin , an E-ring Modified . . . .
Bom et al., “The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity”,J. Med. Chem., 2000, 43, 3940-3980.
Bomgaars, et al., “The Development of Camptothecin Analogs in Childhood Cancers,” Oncologist 6:506-516 (2001).
Cao et al., “Alkyl Esters of Camptothecin and 9-Nitrocamptothecin: Synthesis, in Vitro Pharmacokinetics, Toxicity, and Antitumor Activity”,J. Med. Chem, 1998, 41, 31-37.
Dallavalle et al. “Novel 7-Substituted Camptothecins with Potent Antitumor Activity”,J. Med. Chem, 2000, 43, 3963-3969.
Del poeta et al., “Comparison of In Vitro Activities of Camtothecin and Nitidine Derivatives Against Fungal and Cancer Cells”,Antimicrobial Agents and Chemotherapy, Dec. 1999, 2862-2868.
Garcia-Carbonero et al., “Current Perspectives on the Clinical Experience, Pharmacology and Continued Development of the Camptothecins”,Clinical Cancer Research, Mar. 2002, vol. 8, 641-661.
Keskin, et al., “Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure”, Anti Cancer Drug Design, 15:2:78-98 (2000).
Kingsbury et al., “Synthesis of Water-Soluble (Aminoalkyl)camptothecin Analogues: Inhibition of Topoisomerase I and Antitumor Activity”,J. Med. Chem, 1991, 34, 98-107.
Lavergne et al.,Ann. N.Y. Acad. Sci. 2000, 922:100-111.
Lerchen, “Milestones in Camptothecin Research,” Drugs of the Future 27:869-876 (2002).
Maliepaard et al., “Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918,”Clinical Cancer Research7:935-941, 2001.
Nomoto et al., “Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f,”Jpn. J. Cancer Res. 89:1179-1186, 1998.
O'Leary et al., “Camptothecins: a Review of their Development and Schedules of Administration”,European Journal of Cancer, 1998, vol. 54, No. 10, 1500-1508.
Perego et al., “A Novel 7-modified Camptothecin Analog Overcomes Breast Cancer Resistance Protein-associated Resistance in a Mitoxantrone-selected Colon Carcinoma Cell Line”,Cancer Research, Aug. 15, 2001, 61, 6034-6037.
Pollack et al., “Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo,” Cancer Research 59:4898-4905, 1999.
Saltz L. et al., “CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer”, European Journal of Cancer, 1996, vol. 32A, No. Suppl. 3, pp. 524-531.
Sawada et al., “Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins”,Chem. Pharm. Bull., 1991, 39(10), 2574-2580.
Sawada et al., “Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin”,Chem. Pharm. Bull., 1991, 39(6) 1446-1454.
Shabat D et al., “Multiple event activation of a generic prodrug trigger by antibody catalysis”, Proceedings of the National Academy of Sciences of USA, 96:6925-6930, Jun. 1999.
Singer et al., “Conjugation of Camptothecins to Poly-(L-Glutamic Acid)”, Annals of the New York Academy of Sciences, 2000, vol. 922, pp. 136-150.
Takayama et al., “Synthesis of a New Class of Camptothecin Derivatives, The Long-Chain Fatty Acid Esters of 10-Hydroxycamptothecin, as a Potent Prodrug Candidate, and Their In Vitro Metabolic Conversion by Carboxylesterases”,Bioorganic&Medicinal Chemistry Letters, 1998, 8, 415-518.
Wall et al., “Camptothecin and Taxol: Discovery to Clinic—Thirteenth Bruce F. Cain Memorial Award Lecture”,Cancer Research, Feb. 15, 1995, 55, 753-760.
Wall et al., “Plant Antitumor Agents, 30.1a,bSynthesis and Structure Activity of Novel Camptothecin Analogs”,J. Med. Chem., 1993, 36, 2689-2700.
XP 002033248, ABSTRACT, WPI, vol. 46, N0. 89.
XP 002033250 ABSTRACT, WPI, vol. 45, N0. 89.
Zhao et al., “Synthesis, Topoisomerase I Inhibitory Activity and In Vitro Cytotoxicity of Camptothecin Derivatives Bearing Five-Membered Heterocycle Containing 10-Substituents”,Anti-Cancer Drug Design, 1998, 13, 145-157.
California Pacific Medical Center
Catholic Healthcare West
Desai Rita
Moran Tom M.
LandOfFree
Nitrogen-based homo-camptothecin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen-based homo-camptothecin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen-based homo-camptothecin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3465105